Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid

Atypical lung carcinoid is a rare subtype of lung cancer, comprising 0.05% of all thoracic malignancies. In our case of a patient with metastatic atypical lung carcinoid, next-generation sequencing of the resected tumor identified a CCDC6-RET fusion. The patient initiated treatment with the oral selective RET inhibitor selpercatinib (LOXO-292) on a phase I/II study (NCT03157128) and had a partial response to therapy. Completing next-generation sequencing on rare tumors has become increasingly important in order to identify potential driver mutations and clinical trial opportunities for our patients.